RxDoctor Payments Data

Alok Bhargava, MD

Neurology with Special Qualifications in Child Neurology · Farmington, CTNPI 1114980968

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,036 of the $26,530 with a category attached, or 68.0%. Neurelis, Inc. accounts for 77.6% of it on its own, with 24 other manufacturers making up the rest.

$26,530in general payments, 2019–2025

Across 449 payments — averaging $59.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$21K
  • Tris Pharma Inc$2K
  • UCB, Inc.$783
  • Takeda Pharmaceuticals U.S.A., Inc.$535
  • Ironshore Pharmaceuticals Inc.$516
  • Supernus Pharmaceuticals, Inc.$449
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$18,03668%
  • Food & beverage$8,47932%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,530 in reported general payments places this provider in the 85th percentile of 28 neurology with special qualifications in child neurology providers in Connecticut.

See all neurology with special qualifications in child neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,848
Medicare patients
34
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LamictalLamotrigine22$35,561
Tegretol XrCarbamazepine21$7,913
ConcertaMethylphenidate Hcl12$5,310
Carbamazepine ErCarbamazepine16$3,683
Clonidine Hcl ErClonidine Hcl17$3,453
Risperidone49$2,012
Lacosamide17$1,479
Divalproex Sodium40$1,262
Methylphenidate ErMethylphenidate Hcl23$1,158
DilantinPhenytoin Sodium Extended16$1,152
Topiramate45$1,066
Levetiracetam40$1,046
Aripiprazole15$1,031
Perphenazine11$985
Sertraline Hcl44$749

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →